Kraig Biocraft Laboratories (OTCQB: KBLB) announced that it has deployed one million genetically engineered silkworm eggs across multiple production facilities in Vietnam as part of a spring scale-up effort that could eventually produce approximately 10 metric tons of recombinant spider-silk cocoons per month.
Spider silk has attracted scientific interest, due to its impressive mechanical properties, for decades. By weight, the fiber can be stronger than steel and tougher than many high-performance synthetic materials. The challenge has been viable mass production, since spiders cannot be farmed easily due to their territorial behavior.
The company’s approach modifies domesticated silkworms so they spin fibers incorporating the desired spider-silk proteins. The insects retain their natural spinning process, allowing the fiber to be produced using traditional sericulture methods rather than industrial reactors.
Kraig Labs says it is preparing initial shipments of the biodegradable recombinant Spider Silk material to several unannounced global brands as part of pilot development programs and first commercial deliveries.
From Lab Research to Industrial Production
Kraig Labs first reported integrating spider-silk genes into silkworms more than a decade ago. The work was later described in a peer-reviewed study in the Proceedings of the National Academy of Sciences, which reported that composite fibers produced by transgenic silkworms were tougher than conventional silkworm silk and approached the toughness of natural dragline spider silk.
The research drew widespread attention at the time, including coverage in science publications and mainstream media following a press conference at the University of Notre Dame announcing the breakthrough.
The technology is still attracting interest from the leading authorities, as the March issue of National Geographic examines efforts to commercialize spider silk and highlights genetically engineered silkworms as a potential pathway to scalable production.
Rare Precedent for Engineered Animal Products
Commercial products derived from genetically engineered animals remain uncommon.
One example is ATryn®, a therapeutic antithrombin protein produced in the milk of genetically modified goats. The drug was approved in Europe in 2006 and by the U.S. Food and Drug Administration in 2009 after more than two decades of development.
Kraig’s platform differs from pharmaceutical production because the silkworm directly produces a structural fiber rather than a purified biological compound.
If the company succeeds in maintaining industrial-scale production, it would represent one of the few examples of a transgenic animal system used for commercial manufacturing outside pharmaceuticals.
Hybrid Fibers Today, Purer Silk Tomorrow
Current production fibers are hybrid composites combining traditional silkworm silk proteins with spider-silk proteins. Kraig Labs stated that laboratory testing of the material has shown tensile strengths for some samples approaching 1.8 gigapascals and elasticity above 38%.
The company is also exploring a more ambitious genetic design using sequences from the Darwin’s bark spider, known for producing some of the toughest natural silk fibers measured. That research aims to replace the silkworm’s native silk genes with spider-silk genes, potentially allowing the insects to produce fibers composed largely of spider silk proteins. Results from that work have not yet been announced.
Ancient Industry Meets Modern Genetics
Sericulture is the cultivation of silkworms for silk production, which dates back more than a thousand years and remains a major industry in Asia.
By combining that historical production system with modern gene-editing techniques, Kraig Labs is attempting to turn spider silk from a laboratory material into a commercially manufactured fiber.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com.
About 24/7 Market News
In today’s fast-moving markets, visibility is critical. 24/7 Market News (24/7) provides a comprehensive suite of investor relations and public relations solutions designed to enhance corporate awareness efficiently and effectively. Whether supporting established companies seeking broader exposure or emerging issuers looking to expand their reach, 24/7 delivers targeted coverage through news distribution, analyst reports, featured editorial content, and multi-channel amplification across financial platforms, social media, and investor communities.
Our services are designed to increase visibility, support investor engagement, and strengthen long-term shareholder confidence, while maintaining a commitment to transparency and compliance with applicable regulations.
For analyst report coverage, customized investor relations campaigns, press release distribution, or other tailored communications solutions, contact sales@247marketnews.com to learn more.
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs”) is a biotechnology company focused on the development and commercialization of advanced biomaterials through genetic engineering. The company is best known for its work in producing recombinant spider silk using genetically engineered silkworms, an approach designed to overcome the long-standing challenges of harvesting spider silk at scale.
With growing interest in sustainable and high-performance materials, Kraig Labs is positioning itself at the intersection of biotechnology and advanced materials science, seeking to deliver novel fiber solutions to global markets.
Kraig Labs was featured on the cover of the March 2026 issue of National Geographic. Read the National Geographic cover story.
For more information, visit www.kraiglabs.com.
Disclaimer
This is a paid editorial communication provided for informational purposes only. 24/7 is a third-party media provider that currently owns shares of Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB). These shares are held in inventory and may be sold at the editor’s discretion. 24/7 has been compensated for providing ongoing market awareness, outreach, and related services on behalf of KBLB.
This communication may include technical analysis and forward-looking statements and should not be construed as financial or investment advice. Investing in securities involves risk, including the potential loss of principal. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
For further information, visit 247marketnews.com or go.247marketnews.com/kblb-
disclosure/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are subject to various risks and uncertainties and include, but are not limited to, statements regarding the Company’s ability to grow its business and other statements that are not historical facts. Forward-looking statements are often identified by words such as “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar expressions.
Actual results may differ materially from those expressed or implied in these forward-looking statements due to a variety of factors, including, without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission (SEC).
Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by applicable law.
Media Contact
24/7 Market News
editor@247marketnews.com
